To play this presentation please log in.
Don't have an account?
Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.
Faculty
John P Leonard
MD
NYU Grossman School of Medicine, NYU Langone Health, New York, New York
Laura and Isaac Perlmutter Professor of Hematology and Medical Oncology, Director, Division of Hematology and Medical Oncology, Director, Center for Blood Cancers, Senior Advisor to the Dean/CEO and Chief Clinical Officer for Enterprise Cancer Strategy and Operations, Interim Director, Laura and Isaac Perlmutter Cancer Center
TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of non-Hodgkin lymphoma.
LEARNING OBJECTIVES
- Identify patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) for whom CD79b-targeted therapy as a component of first-line treatment would be appropriate.
- Understand published and recently presented clinical research findings with CD19-targeted monoclonal antibodies in combination with immunomodulatory agents for relapsed/refractory (R/R) follicular lymphoma (FL), and employ this information as part of patient education discussions.
- Assess available clinical trial findings informing the use of CD19-directed chimeric antigen receptor T-cell therapy for R/R FL and DLBCL, and counsel appropriately selected patients regarding the potential benefits of this therapeutic strategy.
- Evaluate the available trial findings with bispecific antibodies targeting CD20 x CD3 in patients with FL and DLBCL, and determine the role of these agents in clinical management.
- Evaluate published clinical research findings establishing the efficacy and safety of Bruton tyrosine kinase (BTK) inhibitors as a component of first-line therapy for mantle cell lymphoma (MCL), and assess the current and potential future clinical role of various BTK inhibitor-based strategies for patients newly diagnosed with the disease.
- Recall new data with agents and strategies currently under investigation for various non-Hodgkin lymphoma subtypes, and discuss ongoing trial opportunities with eligible patients.
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Video Interview: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Video Lecture: Research To Practice designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 1.25 (video) and 1 (lecture) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.
PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
HOW TO USE THIS CME ACTIVITY
To receive credit for an activity in this series, the participant should review the CME information, listen to or view the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation. Program location URLs are noted below:
Video Interview: ResearchToPractice.com/OncologyTodayPostASH25/NHL/Video and evaluation ResearchToPractice.com/OncologyTodayPostASH25/NHL/Video/CME.
Video Lecture: ResearchToPractice.com/OncologyTodayPostASH25/NHL/Presentation and evaluation ResearchToPractice.com/OncologyTodayPostASH25/NHL/Presentation/CME.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
John P Leonard, MD
Richard T Silver Distinguished Professor of Hematology and Medical Oncology
Senior Associate Dean for Innovation and Initiatives
Weill Cornell Medicine
New York, New York
Consulting Agreements: AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Caribou Biosciences Inc, Eisai Inc, Foresight Diagnostics, Genentech, a member of the Roche Group, Grail Inc, Kyowa Kirin Co Ltd, Novartis, Ono Pharmaceutical Co Ltd, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sail Biomedicines, Teva Pharmaceutical Industries Ltd, Treeline Biosciences; Contracted Research: Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc; Data and Safety Monitoring Boards/Committees: BeiGene Ltd, Genentech, a member of the Roche Group; Stock Options — Private Companies: Treeline Biosciences.
EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, and Incyte Corporation.
Release date: April 2025
Expiration date: April 2026
After completing the post-test, learners may download and review the answers here in order to identify further areas of study.
Abramson JS et al. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): A global phase 3, randomised, open-label trial. Lancet 2024;404(10466):1940-54. Abstract
Brem E et al. Odronextamab monotherapy in previously untreated patients with high-risk follicular lymphoma (FL): Results of the safety lead-in of the phase 3 Olympia-1 study. ASH 2024;Abstract 4411.
Dickinson MJ et al. Fixed-duration glofitamab monotherapy continues to demonstrate durable responses in patients with relapsed or refractory large b-cell lymphoma: 3-year follow-up from a pivotal phase II study. ASH 2024;Abstract 865.
Dreyling M et al. High-risk subgroups and MRD: An updated analysis of the phase 3 ECHO trial of acalabrutinib with bendamustine/rituximab in previously untreated mantle cell lymphoma. ASH 2024;Abstract 1626.
Dreyling M et al. Role of autologous stem cell transplantation in the context of ibrutinib-containing first-line treatment in younger patients with mantle cell lymphoma: Results from the randomized Triangle trial by the European MCL network. ASH 2024;Abstract 240.
Falchi L et al. Single-agent mosunetuzumab produces high complete response rates in patients with newly diagnosed follicular lymphoma: Primary analysis of the Mithic-FL1 trial. ASH 2024;Abstract 340.
Fenske TS et al. Lack of benefit of autologous hematopoietic cell transplantation (auto-HCT) in mantle cell lymphoma (MCL) patients (pts) in first complete remission (CR) with undetectable minimal residual disease (uMRD): Initial report from the ECOG-ACRIN EA4151 phase 3 randomized trial. ASH 2024;Abstract LBA-6.
Gaballa S et al. Evaluation of AZD0486, a novel CD19xCD3 T-cell engager, in relapsed/refractory diffuse large b-cell lymphoma in an ongoing first-in-human phase 1 study: High complete responses seen in CAR-T-naive and CAR-T-exposed patients. ASH 2024;Abstract 868.
Gregory GP et al. Primary results of patient-reported outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma treated with glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) versus rituximab plus GemOx (R-GemOx) from the phase III Starglo study. ASH 2024;Abstract 5132.
Hou J-Z et al. Escalating doses of AZD0486, a novel CD19xCD3 T-cell engager, result in high complete remissions with rapid clearance of minimal residual disease in patients with relapsed/refractory follicular lymphoma. ASH 2024;Abstract 341.
Jerkeman M et al. Acalabrutinib and rituximab in elderly patients with newly diagnosed mantle cell lymphoma including a matched population-based external comparator- the nordic lymphoma group NLG-MCL8 (ALTAMIRA) phase II trial. ASH 2024;Abstract 747.
Ladetto M et al. Impact of rituximab maintenance added to ibrutinib-containing regimens with and without ASCT in younger, previously untreated MCL patients: An analysis of the Triangle data embedded in the Multiply project. ASH 2024;Abstract 237.
Lewis D et al. Ibrutinib-rituximab is superior to rituximab-chemotherapy in previously untreated older mantle cell lymphoma patients: Results from the international randomised controlled trial, Enrich. ASH 2024;Abstract 235.
Matasar M et al. Efficacy and safety of odronextamab monotherapy in patients (Pts) with diffuse large B-cell lymphoma (DLBCL) progressing after CAR T-cell therapy: Primary analysis from the ELM-1 study. ASH 2024;Abstract 866.
Morschhauser F et al. Epcore DLBCL-3 first disclosure: Fixed-duration epcoritamab monotherapy in older (≥75 y), anthracycline-ineligible patients with previously untreated large B-cell lymphoma. ASH 2024;Abstract 867.
Neelapu SS et al. 5-year follow-up analysis from ZUMA-5: A phase 2 trial of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed/refractory indolent non-Hodgkin lymphoma. ASH 2024;Abstract 864.
Schuster SJ. Bispecific antibodies for the treatment of lymphomas: Promises and challenges. Hematol Oncol 2021;39(Suppl 1):113-6. Abstract
Sehn LH et al. Tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Results from a phase 3 study (inMIND). ASH 2024;Abstract LBA-1.
Shadman M et al. Mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies including those with a history of POD24: 4-year follow-up of a pivotal phase II study. ASH 2024;Abstract 4407.
Stepan L et al. Circulating tumor DNA (ctDNA) as an early outcome predictor in patients (pts) with second-line (2L) large b-cell lymphoma (LBCL) after lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) treatment (tx) from the phase 3, randomized Transform study. ASH 2024;Abstract 72.
Tilly H et al. Polatuzumab vedotin in previously untreated diffuse large b-cell lymphoma. N Engl J Med 2022;386(4):351-63. Abstract
Wagner-Johnstone ND et al. Addition or substitution of acalabrutinib in intensive frontline chemoimmunotherapy for patients ≤ 70 years old with mantle cell lymphoma: Outcomes of the 3-arm randomized phase II intergroup trial ECOG-ACRIN EA4181. ASH 2024;Abstract 236.
Wang M et al. Acalabrutinib plus bendamustine and rituximab in untreated mantle cell lymphoma: Results from the phase 3, double-blind, placebo-controlled ECHO trial. EHA 2024;Abstract LB3439.